PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.27 ^USD	+0.31%		+23.63%	-34.21%

Mar. 28	B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating	MT
Mar. 27	Empire Metals targets key milestones in Australia	AN

PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023

March 27, 2024 at 07:30 am EDT

PDS Biotechnology Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 42.94 million compared to USD 40.85 million a year ago. Basic loss per share from continuing operations was USD 1.39 compared to USD 1.43 a year ago.

Latest news about PDS Biotechnology Corporation

B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating	Mar. 28	MT
Empire Metals targets key milestones in Australia	Mar. 27	AN
Transcript : PDS Biotechnology Corporation, 2023 Earnings Call, Mar 27, 2024	Mar. 27
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
PDS Biotechnology Corporation Announces Publication of Preclinical Research	Mar. 13	CI
PDS Biotechnology Names Kirk Shepard as Chief Medical Officer	Jan. 22	MT
PDS Biotechnology Corporation Announces Executive Changes	Jan. 22	CI
Apyx Medical Names Matthew Hill as CFO	Nov. 28	MT
PDS Biotechnology Appoints Lars Boesgaard as Finance Chief	Nov. 28	MT
Pds Biotech Announces CFO Changes	Nov. 28	CI
PDS Biotechnology Corporation Announces Resignation of Matthew Hill as Principal Financial Officer and Principal Accounting Officer, Effective December 1, 2023	Nov. 28	CI
Oppenheimer Adjusts PDS Biotechnology Price Target to $20 From $23, Maintains Outperform Rating	Nov. 15	MT
Transcript : PDS Biotechnology Corporation, Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print	Nov. 14	DJ
NetScientific's portfolio company updates on cancer trial	Nov. 09	AN
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients	Nov. 09	CI
NetScientific investee claims promising results in biomarker study	23-10-23	AN
PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO	23-10-23	CI
PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer	23-10-11	CI
NetScientific portfolio company updates on cancer trial	23-10-03	AN
Transcript : PDS Biotechnology Corporation - Special Call	23-10-03
PDS Biotechnology Corporation Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA	23-10-03	CI
PDS Biotechnology Investigational Vaccine Shows 'Active Neutralization' of Multiple Influenza Viruses in Preclinical Studies	23-09-20	MT

Chart PDS Biotechnology Corporation

Duration

Period

More charts

Company Profile

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Investor Meeting - Key Opinion Leader

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.27 USD

Average target price

14.4 USD

Spread / Average Target

+340.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PDS BIOTECHNOLOGY CORPORATION	-34.21%	120M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs